Form 4: Glaukos Director Mark Foley Receives Equity Grant

Director Mark Foley acquired 1,878 restricted stock units and 2,987 stock options as part of the Glaukos Director Compensation Policy.

Summary

• Director Mark J. Foley was granted 1,878 restricted stock units (RSUs) on May 28, 2026.
• The director also received 2,987 stock options with an exercise price of $53.57.
• The total beneficial ownership for the director following these transactions is 60,267 shares.
• Both the RSUs and the stock options vest in full on the one-year anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Equity-based compensation aligns director interests with long-term shareholder value.
• The grants are part of a standard, pre-established Director Compensation Policy.

Negatives

• The issuance of new equity results in minor dilution to existing shareholders.

Risks

• Future share price volatility may impact the ultimate value of the granted equity instruments.

Future Outlook

The equity grants vest in one year, indicating a commitment to the company's long-term performance.

Management Comments

• The transactions were executed pursuant to the Issuer's Director Compensation Policy.

Industry Context

StockSavvy.ai notes that standard equity compensation for board members is a common practice in the medical device sector to ensure alignment with corporate governance standards.

Comparison to Industry Standards

• The use of annual RSU and option grants is consistent with compensation structures at peer medical technology companies like Alcon or Sight Sciences.

Corporate Governance

Stakeholder Impact

• Minor dilution for shareholders due to the issuance of new equity.

Next Steps

• Vesting of equity grants on May 28, 2027.

Key Dates

Keywords

Glaukos, GKOS, Director Compensation, Insider Trading, Equity Grant, Form 4